Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]

Core Viewpoint - Haier Biomedical is experiencing significant growth driven by its diversified business model and technological advancements in the life sciences and medical device sectors, with a focus on low-temperature storage, smart medication, and laboratory solutions [2][8]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical reported a revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [2]. - The revenue from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in the first half of 2025, marking a year-on-year increase of 7.27 percentage points [3]. Group 2: Industry Position and Innovations - Haier Biomedical holds a leading position in various segments, with its smart medication market share ranking among the top three in the industry, and over 50% market share in blood plasma collection solutions [4]. - The company has introduced innovative products such as a disposable leukocyte-reducing blood bag and an automated blood component separator, enhancing customer loyalty and profitability [4]. Group 3: Technological Advancements - The company has increased its R&D investment by 11.61%, accounting for 13.39% of its revenue, focusing on AI technology integration and new product development [6]. - Haier Biomedical has established a multi-layer AI infrastructure, enabling deep integration of AI with various applications, such as the IncGPT-Med model for smart medication [6][7]. Group 4: Growth Strategy - The growth strategy is based on optimizing industry structure, expanding overseas, and leveraging both internal development and external acquisitions [8][9]. - The company has expanded its presence to over 150 countries, with a notable 30% year-on-year increase in overseas revenue during the reporting period [8]. Group 5: Future Outlook - Haier Biomedical aims to enhance its global competitiveness by focusing on four major industries and accelerating the development of innovative products and solutions [9].

Core Viewpoint - Haier Biomedical is experiencing significant growth through its diversified industrial structure and digital transformation strategy, achieving a revenue of 1.196 billion yuan and a net profit of 143 million yuan in the first half of 2025, driven by the synergy of four major industries and AI technology [1] Group 1: Industrial Performance - The company has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with new industries (smart medication, blood technology, laboratory solutions) accounting for 47% of revenue in the first half of 2025, up from 38% in 2023 [2] - Each industry has established a leading position in its respective segment, with the smart medication sector addressing hospital drug management inefficiencies and achieving a top-three market share in automated medication [3] - The blood technology sector holds over 50% market share in plasma collection, introducing new products that enhance customer loyalty and profitability [3][4] Group 2: Technological Advancements - The company is leveraging AI and digital technologies to create a competitive edge, with R&D investment increasing by 11.61% to 13.39% of revenue, focusing on AI integration and new product development [5] - A multi-layered AI architecture has been established, enabling deep integration of AI with various applications, such as the IncGPT-Med model that improves medication handling efficiency [5][6] - The company has seen a 48% increase in patent applications and has established two new R&D centers, reinforcing its technological barriers [6] Group 3: Growth Strategy - The growth potential of Haier Biomedical is driven by a combination of industrial structure optimization, overseas expansion, and internal and external growth strategies [7] - The company has expanded its presence to over 150 countries, with a 30% year-on-year increase in overseas revenue, particularly benefiting from localized strategies in emerging markets [7][8] - Continuous R&D investment and strategic acquisitions have strengthened the company's capabilities in low-temperature storage and laboratory solutions, while also rapidly building platforms in smart medication and blood technology [8]

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, covering low-temperature storage, smart medication, blood technology, and laboratory solutions [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1] Business Transformation - The revenue share from new industries (smart medication, blood technology, laboratory solutions, etc.) increased from 38% in 2023 to 47% in the first half of 2025, a year-on-year increase of 7.27 percentage points [1] International Expansion - The company's products are now available in over 150 countries and regions, with five new localized platforms established in Japan, Brazil, and others during the reporting period [1] - The localized strategy has shown significant results, with overseas revenue growing by over 30% year-on-year, and the second quarter's revenue scale and growth rate reaching a new high for 2023 [1]

格隆汇8月26日丨海尔生物(688139.SH)发布2025年半年度报告，报告期实现营业收入11.96亿元，同比下 降2.27%；归属上市公司股东的净利润1.43亿元，同比下降39.09%；扣除非经常性损益后的归属于上市 公司股东的净利润1.23亿元，同比下降41.68%；基本每股收益0.45元。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-043 青岛海尔生物医疗股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第三届监事会第六次会议于 2025 年 8 月 26 日下午 14:00 以现场结合通 讯方式召开，现场会议在青岛市崂山区盈康一生大厦 19 楼会议室举行。本次会 议的通知于 2025 年 8 月 15 日以电子邮件方式送达全体监事。本次会议应出席监 事 3 人，实际出席监事 3 人，会议由江兰主持。会议的召集和召开程序符合有关 法律法规、规范性文件和公司章程的规定，会议决议合法、有效。 二、监事会会议审议情况 本次会议由江兰主持，经全体监事认真审议并表决，本次会议通过了如下议 案： （一） 审议通过《关于审议公司 2025 年半年度报告及摘要的议案》 公司 2025 年半年度报告及摘要的内容详见与本公告同日在上海证券交易所 网站（http:/ ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 1.195 billion, a decrease of 2.27% compared to the same period last year[17]. - Total profit decreased by 39.66% year-on-year to CNY 156.19 million, while net profit attributable to shareholders fell by 39.09% to CNY 142.74 million[17]. - The net cash flow from operating activities decreased by 39.87% to CNY 35.64 million, primarily due to increased operating expenses[19]. - Basic earnings per share fell by 39.19% to CNY 0.45[18]. - The company's net profit after deducting the impact of share-based payments for the first half of the year is CNY 149,638,753.59, a decrease of 38.11% compared to the same period last year[25]. - The company reported a total profit of CNY 156,193,043.70 for the first half of 2025, down from CNY 258,868,887.07 in the same period of 2024[173]. - The net profit for the first half of 2025 was CNY 147,213,041.40, down 38.4% from CNY 239,137,127.93 in the first half of 2024[173]. - The total operating profit for the first half of 2025 was CNY 5,840,349.77, compared to CNY 129,483,050.75 in the same period of 2024, indicating a significant decline[177]. Revenue and Market Performance - The company's overseas market revenue reached CNY 427 million, representing a year-on-year increase of 30.17%, with the second quarter achieving the highest revenue and growth rate since 2023[19]. - In the first half of 2025, the company achieved a main business revenue of 1.188 billion yuan, with the life sciences segment contributing 599 million yuan and the medical innovation segment contributing 589 million yuan[57]. - Domestic revenue was 761 million yuan, showing a low double-digit year-on-year decline, but the company expects a long-term positive trend driven by industry recovery and increased localization rates[58]. - New industries accounted for 47% of total revenue, achieving a year-on-year growth of 7.27%, with the company holding over 50% market share in plasma collection solutions[59]. - The company's gross profit margin was 46.28%, influenced by new factory ramp-up and an increase in material gross profit margin by 1.4 percentage points[61]. Research and Development - The R&D investment as a percentage of operating revenue increased to 13.39%, up by 1.66 percentage points from the previous year[18]. - The company has accumulated 1,596 patents, focusing on core technologies such as multi-parameter high-precision control and high-speed centrifugation[28]. - The company has established a "four horizontal and four vertical" open innovation system to enhance R&D efficiency and accelerate product innovation[62]. - R&D expenses accounted for 13.39% of revenue, with a year-on-year increase in the number of invention patents by 48%[64]. - The company has invested over 10% of its revenue in R&D annually, employing 828 R&D personnel as of the end of the reporting period[83]. - The company reported a total R&D investment of ¥160,107,590.16, representing an increase of 11.61% compared to the previous year[99]. Assets and Liabilities - Total assets decreased by 3.03% to CNY 5.612 billion compared to the end of the previous year[17]. - The net assets attributable to shareholders decreased by 1.45% to CNY 4.308 billion compared to the end of the previous year[17]. - The company's total liabilities reached CNY 1,087,643,059.53, an increase from CNY 962,455,306.44 in the previous year[170]. - Total liabilities decreased from ¥1,169,332,762.22 to ¥1,053,709,079.97, reflecting a decline of about 10%[167]. - The total amount of raised funds as of the end of the reporting period is CNY 1,231,031,108, with a net amount of CNY 1,156,905,698 after deductions[140]. Market Expansion and Global Presence - The company has established localized operations in 17 countries, including the UK, the US, and Japan, to better serve regional user needs[29]. - The company has a global business presence, with products and solutions applied in over 150 countries and regions, including partnerships with WHO and UNICEF[29]. - The company is actively expanding its global market presence to reduce operational risks associated with industry policy changes[111]. - The company has established experience training centers in regions such as the UAE, Nigeria, Singapore, and the UK, enhancing user engagement[87]. Innovations and Technology - The company has developed digital scene solutions such as smart blood use and smart vaccination, integrating IoT, cloud computing, and AI technologies[28]. - The AI-driven model "IncGPT-Biobank" was developed to improve efficiency in biobank management, achieving an 80% increase in inventory efficiency and a 50% increase in access efficiency[65]. - The company has developed a comprehensive digital solution for blood use and vaccine administration, integrating IoT, cloud computing, and AI technologies[85]. - The company has developed an innovative automated vaccine sorting and storage system, enhancing reliability in vaccine management and addressing cold chain issues[92]. Financial Risks and Management - The company faces potential financial risks from foreign exchange fluctuations, particularly in its export business, which is primarily settled in foreign currencies[110]. - The company aims to enhance its supply chain by optimizing transportation methods and expanding its supplier network to mitigate raw material supply risks[108]. - The company has made commitments to fill the dilution of immediate returns as outlined in the prospectus[133]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 12,814[153]. - The largest shareholder, Qingdao Haier Biomedical Co., Ltd., holds 100,591,463 shares, representing 31.64% of the total shares[157]. - The company did not experience any changes in the total number of ordinary shares or share capital structure during the reporting period[152].

证券代码：688139 证券简称：海尔生物 公告编号：2025-044 青岛海尔生物医疗股份有限公司 | | | 1 | 2019年10月22日实际到账的募集资金 | 1,161,576,074.14 | | --- | --- | | 减：支付的其他发行费用 | 4,670,375.54 | | 募集资金净额 | 1,156,905,698.60 | | 减：募投项目支出金额 | 1,029,056,832.19 | | 其中：以前年度累计使用的募集资金 | 988,378,129.28 | | 本年度投入募投项目支出 | 40,678,702.91 | | 减：永久补充流动资金 | 124,550,000.00 | | 减：期末用于现金管理的暂时闲置募集资金金额 | 87,840,000.00 | | 加：募集资金现金管理产品累计收益金额 | 72,784,401.15 | | 加：累计利息收入扣除手续费金额 | 11,808,991.14 | | 截至2025年6月30日募集资金余额 | 52,258.70 | 2025 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在 ...

青岛海尔生物医疗股份有限公司 关于公司 2025 年度"提质增效重回报"专项行动方案的 青岛海尔生物医疗股份有限公司（以下简称"公司"、"海尔生物"）为践行 "以投资者为本"的上市公司发展理念，维护公司全体股东利益，增强投资者信 心，促进公司长远健康可持续发展，基于对公司未来发展前景的信心和对公司价 值的认可，已连续两年发布"提质增效重回报"专项行动方案。根据 2025 年 3 月 29 日发布的《海尔生物"提质增效重回报"2024 年度评估报告暨 2025 年度 行动方案》，报告期内公司积极开展和落实各项工作，现将 2025 年上半年的主要 工作成果报告如下： 一、 加快发展新质生产力，聚焦四大产业，夯实全球市场竞争力 在人工智能底座深度融合的基础上，报告期内四横四纵平台加强联动，驱 动研发效率提升、技术成果产出加快和产品创新提速。上半年公司研发投入 1.60 亿元，占营业收入的比重为 13.39%；公司新品研发周期同比缩短 6%，发明专利 累计获得数同比增长 48%，累计 32 项成果被鉴定为国际领先水平成果，牵头或 参与起草国家/行业/地方团体等标准 64 项，获得省级以上科技奖励 45 项，上半 年荣 ...

海尔生物公告，2025年上半年营业收入11.96亿元，同比下降2.27%。归属于上市公司股东的净利润1.43 亿元，同比下降39.09%。基本每股收益0.45元／股，同比减少39.19%。 ...